GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » YoY Rev. per Sh. Growth

Imugene (ASX:IMU) YoY Rev. per Sh. Growth : 0.00% (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Imugene YoY Rev. per Sh. Growth?

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months. Imugene's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 was 0.00%.

Imugene's Revenue per Share for the six months ended in Dec. 2023 was A$0.00.

Imugene YoY Rev. per Sh. Growth Historical Data

The historical data trend for Imugene's YoY Rev. per Sh. Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imugene YoY Rev. per Sh. Growth Chart

Imugene Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
YoY Rev. per Sh. Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imugene Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
YoY Rev. per Sh. Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Imugene YoY Rev. per Sh. Growth Calculation

YoY Rev. per Sh. Growth is the percentage change of Revenue per Share over the past twelve months.

Imugene's YoY Rev. per Sh. Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY Rev. per Sh. Growth (A: Jun. 2023 )
=(Revenue per Share (A: Jun. 2023 )-Revenue per Share (A: Jun. 2022 ))/ | Revenue per Share (A: Jun. 2022 ) |
=(0-0)/ | 0 |
=N/A %

Imugene's YoY Rev. per Sh. Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY Rev. per Sh. Growth (Q: Dec. 2023 )
=(Revenue per Share (Q: Dec. 2023 )-Revenue per Share (Q: Dec. 2022 )) / | Revenue per Share (Q: Dec. 2022 )) |
=(0-0)/ | 0 |
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Imugene YoY Rev. per Sh. Growth Related Terms

Thank you for viewing the detailed overview of Imugene's YoY Rev. per Sh. Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Imugene (ASX:IMU) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imugene Ltd (ASX:IMU) » Definitions » YoY Rev. per Sh. Growth
Comparable Companies
ASX:IMM ASX:BOT ASX:PYC ASX:OPT ASX:CUV ASX:RAC ASX:DXB ASX:PIQ ASX:ALA ASX:RCE OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
IUGNF:USA
Address
4-6 Bligh Street, Suite 12.01, Level 12, Sydney, NSW, AUS, 2000
Website
https://www.imugene.com
Imugene Ltd specializes in a clinical-stage immuno-oncology company. Its product includes HER-Vaxx,PD1-Vaxx, CF33 and CF33 CD19. HER-Vaxx is a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER2/neu. The company is also developing B-cell peptide cancer vaccines and therapeutics. Its only operating segment being the Research and Development of oncolytic immunotherapies.

Imugene (ASX:IMU) Headlines

No Headlines